Skip to main content
OpenTrials
Completed

NCT Number: NCT02774486

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

The primary cause of being overweight is an imbalance in calories consumed and energy expenditure. A surplus in energy intake might result in body fat deposition and thereby body weight gain. Therefore, food intake regulation is crucial to control the body weight gain.

Appetite regulation plays an important role in determining the food intake, which is a complex process influenced by the individual (physiology and psychology) and environment. Satiation (process that leads to the termination of eating) and satiety (decline in hunger, increase in fullness after a meal has finished) are the precursors of appetite regulation, which may be induced by various food components such as macronutrients, water, alcohol and non-digestible polysaccharides. High viscosity and swellable/bulking food components such as dietary fibre are expected to elicit stronger satiation/satiety than the macronutrients or clear liquid. Due to its unique physicochemical properties, dietary fibre has been recognized as potential ingredient that helps to enhance the sensation of satiety in the upper gut by increasing gastric distension and delaying gastric emptying, which subsequently reduces the food intake.

IQP-AK-102 comprises of a proprietary blend of dietary fibres known to promote a feeling a fullness. The objectives of this study are to evaluate the efficacy and safety of IQP-AK-102 on appetite reduction in overweight subjects during a 4-weeks interval.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Appetite Regulation Appetite Suppression Energy Intake

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Barbara Grube

Berlin, 10709, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, aged 18-65 years
  • BMI ≥25 and BMI <30 kg/m2
  • Generally in good health
  • Regular daily consumption of 3 main meals (breakfast, lunch, dinner)
  • Consistent regular physical activity (≤4 hours of strenuous sportive activity per week) AND willingness to maintain the same level of sport activity throughout the study
  • Commitment to avoid the use of other weight loss and/or management products / programmes during the study
  • Commitment to complete the subject diary correctly and to adhere to the lifestyle recommended for this study
  • Stable concomitant medications (if any)
  • Stable body weight for the last 3 months prior to V1 (less than 5% self-reported change)
  • Subject's agreement to comply with study procedures
  • Negative pregnancy testing (beta HCG-test in urine) at V1 in females of childbearing potential
  • Women of child-bearing potential: willingness to use reliable method of contraception during the study period

Exclusion criteria

  • Known sensitivity to the components of the investigational product
  • Bariatric surgery in the last 12 months prior to V1
  • Abdominal surgery within the last 6 months prior to V1
  • Presence of any active gastrointestinal disease incl. stenosis in the gastrointestinal tract
  • Malabsorption disorders
  • Pancreatitis
  • History of eating disorders like bulimia, anorexia nervosa, binge-eating (within the last 12 months prior to V1)
  • Lack of appetite for any (unknown) reason
  • Use of medications that could influence gastrointestinal functions such as antibiotics, laxatives, opioids, anticholinergics, anti-diarrheals 3 months prior to V1 and during the study
  • Use of medications that could influence body weight (e.g. antidepressants) in the last 3 months prior to V1 and during the study
  • Any medication or use of products for the treatment of obesity (e.g. fat binder, fat burner, satiety products etc.) or treatment that could influence food absorption, in last 3 months before V1 and during the study
  • Gluten allergy
  • History of abuse of drugs, alcohol or medication
  • Exceeding moderate alcohol consumption (≥21 units /week; 1 unit is equal 1⁄2 l of beer, or 200 ml of wine, or 50 ml hard liquor)
  • Smoking cessation within 6 months prior to V1 or during the study (regular smoking at the same level as prior to the study during the study is not an exclusion criteria)
  • Inability to comply with study procedures (e.g. due to language difficulties etc.)
  • Participation in similar studies or weight loss programs within the last 6 months prior to V1 and during the study
  • Participation in other clinical studies within the last 30 days prior to V1 and during the study
  • Clinically relevant deviations of laboratory values
  • Any other reason deemed suitable for exclusion, per investigator's judgement

Treatment and study plan

IQP-AK-102

Device

IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.

Primary outcomes

  1. Changes in appetite before and after breakfast 3 days a week (including one weekend day) using Haber Score (hunger, satiety)

    Time frame: 6 weeks

    • Comparison between week 2 and week 3 (first week of the IP intake) as well as comparison between week 2 and week 6 (last week of the IP intake)

  2. Changes in appetite before and after breakfast 3 days a week (including one weekend day) using VAS (hunger, satiety, fullness, prospective food consumption).

    Time frame: 6 weeks

    • Comparison between week 2 and week 3 (first week of the IP intake) as well as comparison between week 2 and week 6 (last week of the IP intake)

Secondary outcomes

  1. Changes in food intake using the subject diary

    Time frame: 6 weeks

    Measured on the same days as appetite assessment (for breakfast, lunch, dinner, in between meal/snacks), during the run-in phase (three days a week, both weeks) and treatment phase (at first week of the IP intake (week 3),and during the last week of the IP intake, just before the V3, also three days a week).

  2. Changes in body weight using calibrated weighing scales (Tanita BC-420 SMA)

    Time frame: 6 weeks

    Body weight (kg) is measured in subjects wearing underwear and no shoes

  3. Changes in BMI

    Time frame: 6 weeks

    BMI is calculated as body weight (kg)/(height [m])2

  4. Changes in waist circumference

    Time frame: 6 weeks

    Waist circumference (cm) is measured at the level midway between the lateral lower rib margin and the iliac crest

  5. Changes in hip circumference

    Time frame: 6 weeks

    Hip circumference (cm) is measured as the maximal circumference over the buttocks

  6. Changes in body fat content using validated electronic weighing scales according to the Body composition analyser BC-420MA (a bio-impedance analysis (BIA))

    Time frame: 6 weeks

    Measured as % and kg

  7. Changes in fat-free mass using validated electronic weighing scales according to the Body composition analyser BC-420MA (a bio-impedance analysis (BIA))

    Time frame: 6 weeks

    Measured as % and kg

  8. Global evaluation of efficacy by subjects

    Time frame: 6 weeks

    The subjects will evaluate independently the efficacy of the IP (globally scaled evaluation with "very good", "good", "moderate" and "poor").

  9. Global evaluation of efficacy by investigator

    Time frame: 6 weeks

    The investigators will evaluate independently the efficacy of the IP (globally scaled evaluation with "very good", "good", "moderate" and "poor").

  10. Blood pressure

    Time frame: 6 weeks

    Measured using standard devices after an at least 5-minute rest

  11. Pulse rate

    Time frame: 6 weeks

    Measured using standard devices after an at least 5-minute rest

  12. Global evaluation of safety by subjects

    Time frame: 6 weeks

    The subjects will evaluate independently the tolerability of the IP (global scaled evaluation with "very good", "good", "moderate" and "poor").

  13. Global evaluation of safety by investigator

    Time frame: 6 weeks

    The investigators will evaluate independently the tolerability of the IP (global scaled evaluation with "very good", "good", "moderate" and "poor").

Sponsors and collaborators

Lead sponsor

InQpharm Group

Industry

Registry information

Official study title

Open-Label Clinical Investigation to Evaluate Efficacy and Safety of IQP-AK-102 on Appetite Reduction in Healthy Over- Weight Subjects

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
May 17, 2016
Registry last updated
Jan 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.